(HealthDay News) — Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes ...

Novartis reports that Fabhalta® achieved the Phase III APPLAUSE-IgAN primary endpoint, showing slowed kidney-function decline ...

I read your recent column where you said that ivermectin has not been proven to be an effective treatment for cancer. I feel ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 inhibitor (SGLT2-i) slows nodule growth and reduces the need for surgical ...

A comparative effectiveness study of glucose-lowering drugs finds the GLP-1 receptor agonists most protective against ...

The diabetes drug empagliflozin (Jardiance) and an insulin nasal spray both showed promising effects on memory, brain health ...

A type 2 diabetes medication may lower the risk of autoimmune rheumatic diseases like rheumatoid arthritis by 11%, unlike ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in ...

Phenotyping patients can help to identify potential heart failure with preserved ejection fraction (HFpEF) as well as improve patient outcomes.

Diuretics serve as essential but symptomatic therapy in heart failure management, functioning primarily as a “bailout ...